āĻšā§āĻŽHPX âĸ FRA
add
Hisamitsu Pharmaceutical Co Inc
ā§Šā§§.ā§Žā§ĻâŦ
⧍ āĻāĻĒā§āϰāĻŋ, ā§§ā§Ļ:ā§Ģā§Ŧ:⧍ā§Ē PM GMT +⧍ · EUR · FRA · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āϏā§āĻāĻDE-āĻ āϤāĻžāϞāĻŋāĻāĻžāĻā§āĻā§āϤ āϏāĻŋāĻāĻŋāĻāϰāĻŋāĻāĻŋJP-āĻ āĻšā§āĻĄāĻā§ā§āĻžāϰā§āĻāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Šā§¨.ā§Ļā§ĻâŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Šā§§.ā§Žā§ĻâŦ - ā§Šā§§.ā§Žā§ĻâŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
⧍⧧.ā§Ēā§ĻâŦ - ā§Šā§Ģ.ā§Ŧā§ĻâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§Ē.ā§Ģā§ĒāĻā§ JPY
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
TYO
āĻŦāĻžāĻāĻžāϰ āϏāĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
| (JPY) | āύāĻ⧠⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§Š.⧝ā§ŦāĻļāĻ¤Â āĻā§ | ā§§ā§Ļ.ā§Ģā§Ē% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§§.ā§Žā§āĻļāĻ¤Â āĻā§ | ā§Ģ.ā§Ļā§Ģ% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§Ēā§Žā§Ŧ.ā§Žā§Ļ āĻā§ | ā§Ŧ.ā§ā§§% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | â | â |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | â | â |
EBITDA | ā§Ŧā§Ļā§Ŧ.ā§Ēā§ŽÂ āĻā§ | â |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | â | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (JPY) | āύāĻ⧠⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ā§§.ā§§ā§§āĻā§ | -ā§Ģ.ā§Ļā§Š% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Š.ā§Ē⧍āĻā§ | ⧍.⧍ā§Ē% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§.ā§Ļā§āĻļāĻ¤Â āĻā§ | -⧍.ā§Ģā§Ļ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ⧍.ā§ā§¨āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§.ā§Ļā§§Â āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§Ļ.ā§Ļā§§ | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | â | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | â | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
| (JPY) | āύāĻ⧠⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§Ēā§Žā§Ŧ.ā§Žā§Ļ āĻā§ | ā§Ŧ.ā§ā§§% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | â | â |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | â | â |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | â | â |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | â | â |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| â | â |
āϏāĻŽā§āĻĒāϰā§āĻā§
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Tosu and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
ā§§ā§Žā§Ēā§
āϏāĻĻāϰ āĻĻāĻĒā§āϤāϰ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
⧍,ā§ā§¯ā§¯